时间窗扩展的时机:ESCAPE试验中晚期就诊者的启示
该研究对ESCAPE试验中在最后正常时间5.5至12小时随机化的59例受试者(干预组33例、对照组26例)进行亚组分析,比较早期与晚期时间窗的治疗异质性及预后。结果显示扩展时间窗内干预有利于所有临床结局(90天mRS 0-2的绝对风险差19.3%),干预组无症状性脑出血更多(48.5% vs 11.5%,P=0.004),症状性出血无差异;作者认为扩展时间窗患者可能从血管内治疗中获益。
要点
- 扩展时间窗内(最后正常5.5至12小时)血管内治疗有利于90天mRS 0-2等临床结局。
- 干预组无症状性脑出血48.5% vs 对照组11.5%(P=0.004),症状性出血无差异。
- 早期与晚期时间窗受试者间未发现治疗异质性证据。
核心结论
- 扩展时间窗患者可能从血管内治疗中获益,尚需正在进行的随机对照试验以影像识别晚期就诊且脑生理有利者来巩固时间窗与影像选择范式。
研究设计与样本
- ESCAPE试验亚组分析,纳入最后正常时间5.5至12小时随机化的59例受试者(干预组33例、对照组26例),比较早期与晚期时间窗的治疗效应。
诊断标准与关键数值
- 扩展时间窗内干预有利于所有临床结局,90天mRS 0-2的绝对风险差为19.3%。
- 干预组无症状性脑出血48.5% vs 对照组11.5%(P=0.004),症状性颅内出血无差异。
临床应用与阅片要点
- 作者认为扩展时间窗患者可能从血管内治疗中获益。
- 作者指出正在进行的随机对照试验将用影像识别脑生理有利的晚期就诊者,以助确立时间窗选择急性影像人群、影像选择个体治疗的范式。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
BACKGROUND AND PURPOSE: The safety and efficacy of endovascular therapy for large-artery stroke in the extended time window is not yet well-established. We performed a subgroup analysis on subjects enrolled within an extended time window in the Endovascular Treatment for Small Core and Proximal Occlusion Ischemic Stroke (ESCAPE) trial.
MATERIALS AND METHODS: Fifty-nine of 315 subjects (33 in the intervention group and 26 in the control group) were randomized in the ESCAPE trial between 5.5 and 12 hours after last seen healthy (likely to have groin puncture administered 6 hours after that). Treatment effect sizes for all relevant outcomes (90-day mRS shift, mRS 0-2, mRS 0-1, and 24-hour NIHSS scores and intracerebral hemorrhage) were reported using unadjusted and adjusted analyses.
RESULTS: There was no evidence of treatment heterogeneity between subjects in the early and late windows. Treatment effect favoring intervention was seen across all clinical outcomes in the extended time window (absolute risk difference of 19.3% for mRS 0-2 at 90 days). There were more asymptomatic intracerebral hemorrhage events within the intervention arm (48.5% versus 11.5%, P = .004) but no difference in symptomatic intracerebral hemorrhage.
CONCLUSIONS: Patients with an extended time window could potentially benefit from endovascular treatment. Ongoing randomized controlled trials using imaging to identify late presenters with favorable brain physiology will help cement the paradigm of using time windows to select the population for acute imaging and imaging to select individual patients for therapy.
引用
- Evans JW, Graham BR, Pordeli P, et al. Time for a Time Window Extension: Insights from Late Presenters in the ESCAPE Trial. AJNR Am J Neuroradiol. 2017. PMID: 29191873. doi:10.3174/ajnr.A5462
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。